Pfizer begins first human tests of mystery pill PF-07940369

NCT ID NCT07514156

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a new oral drug called PF-07940369 in 30 healthy adults to see if it is safe and how the body processes it. Participants took the drug or a placebo once or twice daily for 14 days while staying at a clinic. The main goal was to check for side effects and measure drug levels in the blood. This is a first step before testing the drug for any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PF-07940369 (oral tablet)
What this could lead to
If this drug is safe, it could move to later trials testing it for a specific disease.
What could go wrong
This is a very early Phase 1 safety study in only 30 healthy people. The drug may not work for any condition or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer Clinical Research Unit - Brussels

    Brussels, Bruxelles-capitale, Région de, B-1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.